All In Biotech

Drug Trial Radar · NCT07405671

Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation

Randomized Evaluation of fleCAinide Safety Versus STandard of Care in Patients With Coronary Artery Disease and Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 988 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

988

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Research Foundation Flanders
First posted
Feb 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether the antiarrhythmic drug flecainide can be used as safely as standard rhythm-control drugs in people with atrial fibrillation (AF) and stable coronary artery disease (CAD). The study includes adults aged 18 years and older who have AF and known but stable coronary artery disease. The main questions this study aims to answer are: * Is treatment with flecainide as safe as standard rhythm-control drugs (sotalol or amiodarone) in this patient group? * Does flecainide lead to similar or fewer serious side effects, hospitalisations, or deaths compared with standard treatment? Researchers will compare patients treated with flecainide to patients treated with standard rhythm-control therapy (sotalol or amiodarone) to see whether flecainide is not worse in terms of safety outcomes. Participants will: * Be randomly assigned to receive either flecainide or standard rhythm-control medication * Take the assigned medication as part of routine clinical care * Attend regular follow-up visits at the hospital and have additional follow-up by telephone * Undergo routine heart tests such as electrocardiograms and echocardiography * Complete questionnaires about symptoms, quality of life, and daily functioning This study follows patients for at least one year and collects information on safety, heart rhythm outcomes, quality of life, and healthcare use.

Conditions

  • Atrial Fibrillation (AF)
  • Coronary Artery Disease

Interventions

  • flecainideDrug

    Flecainide, a class Ic anti-arrhythmic drug Recommended starting dose of 100 to 150 mg per day per os, either spread in 2 equal doses BID or in 1 dose OD with controlled release formulation. Flecainide will always be combined with an AV nodal blocker (beta-blocker or diltiazem/verapamil).

  • Sotalol or AmiodaroneDrug

    Class III anti-arrhythmic drug: Sotalol or amiodarone as per physician preference. Recommended starting doses: * Sotalol: 80 mg BID per os, with a dose adjustment to once daily if the eGFR is between 40 and 60 mL/min. * Amiodarone: loading dose of 600 mg daily per os in divided doses for 1 week, followed by 400 mg daily per os in divided doses for 1 week, and subsequently 200 mg per os once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite safety outcomeTime frame: 1 year

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • AZorg

    Aalst, Belgium · Recruiting

  • Imelda

    Bonheiden, Belgium · Not yet recruiting

  • AZ ST-JAN Brugge A.V.

    Bruges, Belgium · Not yet recruiting

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium · Recruiting

  • Ziekenhuis Oost Limburg

    Genk, Belgium · Not yet recruiting

  • Az Maria Middelares Gent

    Ghent, Belgium · Not yet recruiting

  • AZ St.-Elisabeth Herentals VZW

    Herentals, Belgium · Not yet recruiting

  • Jan Yperman Ziekenhuis

    Ieper, Belgium · Not yet recruiting

  • Algemeen Ziekenhuis Groeninge

    Kortrijk, Belgium · Not yet recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Algemeen Ziekenhuis Delta

    Roeselare, Belgium · Not yet recruiting

  • AZ Rivierenland

    Rumst, Belgium · Not yet recruiting

  • Vitaz

    Sint-Niklaas, Belgium · Not yet recruiting

  • AZ Turnhout

    Turnhout, Belgium · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.